Lipoprotein lipase activity and mass, apolipoprotein C-II mass and polymorphisms of apolipoproteins E and A5 in subjects with prior acute hypertriglyceridaemic pancreatitis
© Coca-Prieto et al; licensee BioMed Central Ltd. 2009
Received: 18 February 2009
Accepted: 17 June 2009
Published: 17 June 2009
Severe hypertriglyceridaemia due to chylomicronemia may trigger an acute pancreatitis. However, the basic underlying mechanism is usually not well understood. We decided to analyze some proteins involved in the catabolism of triglyceride-rich lipoproteins in patients with severe hypertriglyceridaemia.
Twenty-four survivors of acute hypertriglyceridaemic pancreatitis (cases) and 31 patients with severe hypertriglyceridaemia (controls) were included. Clinical and anthropometrical data, chylomicronaemia, lipoprotein profile, postheparin lipoprotein lipase mass and activity, hepatic lipase activity, apolipoprotein C II and CIII mass, apo E and A5 polymorphisms were assessed.
Only five cases were found to have LPL mass and activity deficiency, all of them thin and having the first episode in childhood. No cases had apolipoprotein CII deficiency. No significant differences were found between the non-deficient LPL cases and the controls in terms of obesity, diabetes, alcohol consumption, drug therapy, gender distribution, evidence of fasting chylomicronaemia, lipid levels, LPL activity and mass, hepatic lipase activity, CII and CIII mass or apo E polymorphisms. However, the SNP S19W of apo A5 tended to be more prevalent in cases than controls (40% vs. 23%, NS).
Primary defects in LPL and C-II are rare in survivors of acute hypertriglyceridaemic pancreatitis; lipase activity measurements should be restricted to those having their first episode during chilhood.
Among patients with acute pancreatitis, 1.3 to 3.5% are due to hypertriglyceridaemia, also known as hypertriglyceridaemic pancreatitis [1, 2], some times relapsing and being even more severe than lithiasic acute pancreatitis . Acute hypertriglyceridaemic pancreatitis forms part of the Chylomicronaemia Syndrome, defined as the presence of one or more of the typical signs (eruptive xanthomas, lipidaemia retinalis, recurrent abdominal pain or acute pancreatitis) in a patient with plasma triglyceride concentrations >22.58 mmol/L.
Genetic causes of the syndrome are rare and include deficiency of lipoprotein lipase (LPL), apolipoprotein C-II, and familial inhibitor of LPL. Other genes are also involved in the catabolism of chylomicrons, such as those for apolipoprotein E, apolipoprotein A-V  and glycosylphosphatidylinositol hgih density lipoprotein-binding protein [6, 7] Patients with familial forms of hypertriglyceridaemia in combination with secondary acquired disorders (obesity, diabetes, pregnancy or drugs, including estrogens, retinoids, highly-active antiretroviral drugs) account for most individuals presenting with chylomicronaemia .
Although the presence of chylomicrons is necessary for the development of hypertriglyceridaemic pancreatitis and these are considered to be present when the triglycerides >11.29 mmol/L, it is common in out-patient clinics to see patients with much higher concentrations who are nevertheless asymptomatic and have not required admission for hypertriglyceridaemic pancreatitis. Few studies on the catabolism of triglyceride-rich lipoproteins have been published , with most reports concerning isolated cases with severe chylomicronaemia triggered by drugs or pregnancy [10–17]. Furthermore, additional interest concerns the identification of LPL-deficient patients for the potential use of intramuscular administration of an adeno-associated virus serotype 1 (AAV1) vector encoding the human LPL(S447X) variant cDNA (AAV1-LPL(S447X)), which normalized the chylomicronaemia in LPL-/- mice for more than 1 year  and is providing new data on humans.
We therefore studied LPL mass and activity, hepatic lipase activity, the levels of apolipoprotein C-II and apo E and apo A-V polymorphisms in order to detect any differences between persons with hypertriglyceridaemia who developed hypertriglyceridaemic pancreatitis and those who did not.
We studied 24 patients who were referred to our Lipids Unit after having hypertriglyceridaemic pancreatitis (HP Group). To be included in this group the patients had to have suffered at least one episode of acute pancreatitis (symptoms compatible with raised amylases in blood and urine and/or lipase in blood and morphological involvement of the pancreas on abdominal CT) and triglyceride concentrations on admission >11.29 mmol/L or, failing this, a lipaemic serum. All the patients with hypertriglyceridaemic pancreatitis were studied from several weeks to months after the episode of acute pancreatitis, when they were at home and with no symptoms.
In order to compare the different variables, a control group was recruited consisting of 31 patients referred to our Lipids Unit with severe hypertriglyceridaemia (triglycerides >11.29 mmol/L on at least one occasion), which thus represented a risk of having had hypertriglyceridaemic pancreatitis (HTG Group). As our centre has no paediatric unit, all the participants were older than 14 years of age.
All the patients and controls were being treated with diet and/or lipid lowering drugs. Due to ethical reasons, in no case was the medication stopped or changed because of inclusion in the study.
The clinical records of all the patients with hypertriglyceridaemic pancreatitis were reviewed retrospectively, in order to identify any factors predisposing to chylomicronaemia that could have led to the development of acute pancreatitis. Data were recorded on alcohol consumption, the presence of diabetes mellitus and its degree of control, dietary transgressions, pregnancy, and the intake of oestrogens or other drugs that could potentially increase triglyceride concentrations in predisposed patients (retinoic acid, antiretroviral therapy, corticoids, etc...). We considered moderate alcohol consumption less than 40 g in men and 20 g in women. No patients with alcoholic pancreatitis were included in our series. Previous diagnosis of co-morbidities, such as hypertension, vascular disease, fatty liver and coronary heart disease were also recorded. Because few relatives were available for lipid analyses, family history of hyperlipidemia relied mainly in patient's recall.
The study was approved by the Research and Ethics Committee of Virgen de la Victoria Hospital and all the patients gave written informed consent.
Lipid and Lipoprotein Profile
Venous blood samples were obtained from each subject after a 12-hour fast. The baseline sample was used for lipid analysis, lipoprotein and apolipoprotein fractions and the second sample (drawn from the contralateral arm 15 minutes after administering sodium heparin (100 IU/kg) was used to measure the LPL lipase and hepatic lipase activity and the LPL mass.
The lipoproteins were separated by ultracentrifugation and later precipitation . The separation of the chylomicrons in each sample was done by ultracentrifugation for 30 minutes at 105,000 × g. Because our technique is not able to distinguish between smaller chylomicrons and larger VLDL the lipoprotein obtained were chylomicron-like particles. After chylomicrons-like particles were removed, plasma was ultracentrifugated for 18 hours, 10°C, d 1.006 Kg/L at 105,000 × g, in order to separate VLDL. The infranatant fraction, containing LDL plus HDL, was reconstituted to the original volume and HDL was measured after precipitation of LDL . Cholesterol and triglycerides were measured in plasma and in each lipoprotein fraction by commercial enzymatic methods (ABX, Montpelier, France). The plasma apolipoproteins (A-I, B-100, C-II, C-III, E] were quantified by commercial immunoturbidimetric methods (ABX, and DAIICHI, Tokyo, Japan). These measurements were all done at the Centro de Investigaciones Médico-Sanitarias (CIMES) of Malaga University, Spain.
Lipoprotein Activity and Mass
The LPL activity assay was done on an Intralipid 10% emulsion and the hepatic lipase activity was measured using a gum Arabic-stabilized emulsion of triolein as previously published [21, 22]. Each sample for LPL and hepatic lipase activities was assayed in triplicate and two standard samples were analysed in each assay. The activities of LPL and hepatic lipase are shown as mU/mL of plasma. One mU corresponds to nmol of fatty acid released per minute at 25° .
The LPL mass was measured by ELISA (19), using purified chicken antibodies to coat the wells and the monoclonal antibody 5D2, both against bovine LPL (Courtesy of Dr J. Brunzell, Seattle, USA). The mean values of all the samples were calculated for at least 3 different dilutions. The results are expressed in ng/mL. Purified bovine milk LPL was used as an assay standard.
Postheparin values from 20 healthy subjects were: LPL activity 56 ± 23 mU/mL (range 17–92) and LPL mass 254 ± 108 ng/mL (range 117–419).
Polymorphisms of Apolipoproteins E and A-V
Genomic DNA was extracted by BioRobot® EZ1 (QIAGEN). Genotyping for Apo E and APO A5 polymorphisms was carried out by PCR and restriction fragment analysis. Amplification reactions were performed in an iCycler iQ™ (BioRad) thermal cycler employing iQ™ Supermix (BioRad) as reaction mix. The primers and thermal protocols used were as previously described [24, 25], with minor modifications.
Comparison of the quantitative variables between groups was done with the Student t test for independent data and analysis of variance (ANOVA), or the Mann-Whitney "U" test and the Kruskal-Wallis "H" test if the variables failed to adjust to normality. Analysis of the association of qualitative characteristics was done with the χ-square test or Fisher's exact test if the expected frequency was less than 5. All the tests were bilateral and the results considered significant if the p < 0.05. The database and the various tests mentioned were done with the programme SPSS 12.0 (SPSS Inc, Chicago, USA).
Clinical and demographic data
N = 24
N = 31
43 ± 11
46 ± 9
Age first onset AP
40 ± 11
AP Episo N°
2.3 ± 1.9 (1–9)
≥ 3 epis
26.5 ± 4.0
29.3 ± 5.0
Coronary artery disease
Over half the patients with hypertriglyceridaemic pancreatitis had consumed alcohol prior to the episode, four patients (20%) had diabetes mellitus which was to some degree poorly controlled, and one patient had just started steroid therapy for Evans Syndrome. No triggering factor was found in four patients. None of the patients with hypertriglyceridaemic pancreatitis was pregnant or had consumed estrogens. A positive family history of hyperlipidaemia was around 50% in both groups, but probably it was underestimated because many relatives could not be analyzed.
Serum lipids, lipoproteins, apolipoproteins and LPL mass and LPL and HL activities in postheparin and preheparin plasma samples
N = 24
N = 31
6.96 ± 3.72
6.56 ± 1.68
0.83 ± 0.44
0.91 ± 0.47
0.91 ± 0.49
0.88 ± 0.39
2.95 ± 1.47
3.28 ± 1.40
4.29 ± 5.43
2.17 ± 1.53
1.04 ± 0.36
1.10 ± 0.30
0.91 ± 0.32
0.96 ± 0.27
0.11 ± 0.05
0.13 ± 0.07
0.17 ± 0.07
0.20 ± 0.09
0.09 ± 0.04
0.11 ± 0.06
2.8 ± 4
1.7 ± 0.7
Apo E Genotype
Apo A-V, allele S19W
69 ± 44
92 ± 44
164 ± 94
194 ± 84
312 ± 192
411 ± 195
18 ± 11
22 ± 14
clinical data of patients with LPL deficiency
N = 20
N = 30
N = 5
47 ± 8
47 ± 7
23 ± 6
Age first onset AP
40 ± 11
6 ± 6
Episode AP number
1.75 ± 0.85
2.5 ± 0.6
27.4 ± 3.6
29.7 ± 4.8
21.3 ± 1.6
Serum lipids, lipoproteins and apolipoproteins in the three groups
HPND (N = 20)
HTG (N = 30)
HPD (N = 5)
6.36 ± 2.53
6.75 ± 1.58
8.66 ± 6.86
0.78 ± 0.41
0.91 ± 0.49
0.98 ± 0.59
1.01 ± 0.47
0.91 ± 0.39
0.39 ± 0.13
3.21 ± 1.40
3.39 ± 1.32
1.45 ± 1.27
2.95 ± 3.34
2.22 ± 1.58
5.90 ± 7.55
1.14 ± 0.29
1.11 ± 0.28
0.54 ± 0.17
0.98 ± 0.27
0.98 ± 0.25
0.56 ± 0.37
0.11 ± 0.06
0.13 ± 0.07
0.09 ± 0.05
0.17 ± 0.07
0.20 ± 0.09
0.19 ± 0.05
0.07 ± 0.04
0.11 ± 0.06
0.14 ± 0.03
2 ± 3
1.7 ± 0.7
5 ± 7
82 ± 34
95 ± 41
0.4 ± 0.5
179 ± 95
195 ± 86
107 ± 47
365 ± 164
422 ± 190
58 ± 27
19 ± 10
22 ± 14
17 ± 12
Our study focussed on the analysis of post-heparin lipoprotein-lipase activity and the level of apolipoprotein C-II in persons who had survived at least one episode of hypertriglyceridaemic pancreatitis in comparison with persons who were at risk for the same disorder due to having severe hypertriglyceridaemia with triglycerides >10 mmol/L . The study led to the identification of five persons with a deficiency in LPL mass and activity, no case with a deficiency of apolipoprotein C-II and a borderline increase in apo A V S19W polymorphism in HP group.
Our findings are coherent with previous reports, in which the vast majority of cases with severe hypertriglyceridaemia (phenotype I or V) are due to the presence of one or more secondary causes. For example, just five of 123 patients with severe hypertriglyceridaemia (triglycerides>22.58 mmol/L) were deficient in LPL [27, 28]. Additionally, no case of LPL deficiency was reported among 27 adults with hypertriglyceridaemic pancreatitis . Moreover, among 129 patients with severe hypertriglyceridaemia referred to an Endocrinological Department for evaluation, including 26 with acute pancreatitis, no one was found to have LPL deficiency .
Our patients with hypertriglyceridaemic pancreatitis due to LPL deficiency were clinically different from the those with preserved LPL mass and activity, which explain their greater frequency of episodes of recurrent pancreatitis, the onset before adolescence, and the lower weight and body mass index than the patients with hypertriglyceridaemic pancreatitis and preserved LPL mass and activity. Analytically, besides the greater presence and levels of chylomicrons, the patients with a deficit had lower levels of LDL, HDL, apo B-100 and apo A-1. Moreover, the patients with hypertriglyceridaemic pancreatitis without LPL deficiency were more likely to have associations with important environmental factors, such as diabetes, obesity and alcohol consumption. The family association in some of these patients, the lipoprotein profile with marked hyperchylomicronaemia and the onset in childhood, all suggest a diagnosis of familial LPL deficiency, although a definitive diagnosis would require sequencing of the LPL gene or by measuring postheparin plasma LPL activity.
Our study found no differential clinical or analytical traits between the groups with hypertriglyceridaemic pancreatitis without LPL deficiency and the group of patients with severe hypertriglyceridaemia that could be used for identification of patients with hypertriglyceridaemia who might be predisposed to a pancreatic event. Notably, and as opposed to what might be expected , the amount of triglycerides and cholesterol in the chylomicrons did not differ between the two groups either.
The patients were analysed during the stable phase of their hyperlipidaemia, after several weeks or months of treatment and at least several months since their last episode of hypertriglyceridaemic pancreatitis. It is thus more than likely that if the group with hypertriglyceridaemic pancreatitis been studied during the acute phase of the disease and, not whilst they were stable, we would have obtained greater information on those environmental factors that could have triggered the disease, for example dietary transgression such as a high consumption of fatty food or alcohol, cessation of treatment or severe lack of diabetic control. By the contrary, the acute phase of pancreatitis is not the best clinical scenario to measure LPL activity (pain, nasogastric tube, prophilactic heparin, inflammatory state...).
Interaction of environmental factors with certain genetic polymorphisms may also have triggered the onset of hypertriglyceridaemic pancreatitis. The presence of the ε2 or ε4 allele in the apolipoprotein E gene has been associated with severe hypertriglyceridaemia , hypertriglyceridaemic pancreatitis during pregnancy  and higher postprandial levels of hyperlipidaemia . Nevertheless, our groups did not differ in the frequency of the non apo E3/E3 genotypes. Certain polymorphisms in the apo A-V gene have been associated with triglyceride levels in a healthy population  and in persons with severe hypertriglyceridaemia [33, 34] Indeed, severe chylomicronaemia with repeated hypertriglyceridaemic pancreatitis has been reported in two persons with apo A-V deficit [35, 36] One mechanism proposed is that apo A-V lowers triglyceride concentrations by guiding VLDL and chylomicrons to proteoglycan-bound LPL for lipolysis  or simply acting as a cofactor of the enzyme. In a group of persons with hypertriglyceridaemia (triglycerides >3.80 mmol/L), the prevalence of the rare allele S19W of apolipoprotein A-V was found to be 19%, whereas it was only present in 4% of the control subjects . The frequency of this rare allele in our patients was spread unequally; it was absent in the patients with LPL deficiency but was more common in the patients with HPND than in the controls with hypertriglyceridaemia, and may perhaps have contributed to a greater predisposition in the former for the development of pancreatitis due to the chylomicrons. Unfortunately, our study was underpowered to reach any conclusion.
Some limitations, however, should be taken into account interpreting our data. Patients were seen several months after the discharge of the bout of HP; second, many of them have been treated with fibrates, which not only modify lipids but also increase the LPL activity.
We found that a primary defect in the catabolism of TG-rich lipoproteins was rare in patients who had survived a bout of hypertriglyceridaemic pancreatitis. Quantification of the LPL mass and activity should therefore be reserved for patients with a normal body mass index and recurrent acute pancreatitis that started in childhood or adolescence. None of the known factors, such as the presence and amount of fasting chylomicrons, the coexistence of accompanying disease such as obesity or diabetes, or the consumption of alcohol outside the acute phase, enabled the hypertriglyceridaemic patients to be differentiated from those with hypertriglyceridaemia who had developed hypertriglyceridaemic pancreatitis. Nevertheless, certain genetic factors, such as the 19W variant of apo A-V gene or other factors not studied here may predispose patients with hypertriglyceridaemia to manage postprandial fat worse and thereby make them more vulnerable to hypertriglyceridaemic pancreatitis. Further studies along similar lines and with a greater number of patients are required to confirm these findings.
The authors wish to thank Solveig Nilsson and Elena Makoveichuk for help with the lipase measurements. Part of the studies were financed by grants from the Swedish Research Council and from the King Gustaf V and Queen Victoria Research Fund and by grants from Grupos de Investigacion y Desarrollo Tecnologico de la Junta de Andalucia (Grupo consolidado CTS-159).
- Searles GE, Ooi TC: Underrecognition of chylomicronemia as a cause of acute pancreatitis. CMAJ. 1992, 147 (12): 1806-8.PubMedPubMed CentralGoogle Scholar
- Fortson MR, Freedman SN, Webster PD3: Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol. 1995, 90 (12): 2134-9.PubMedGoogle Scholar
- Navarro S, Cubiella J, Feu F, Zambon D, Fernandez-Cruz L, Ros E: Hypertriglyceridemic acute pancreatitis. Is its clinical course different from lithiasic acute pancreatitis?. Med Clin (Barc). 2004, 123 (15): 567-570.View ArticleGoogle Scholar
- Brunzell JD, Deeb SS: Familial Lipoprotein Lipase deficiency, apo C-II deficiency and hepatic lipase deficiency. The Metabolic & Molecular Bases of Inherited Disease. Edited by: Scriver CR, Beaudet BL, Sly WS, Valle D. 2001, New York: McGraw-Hill, II: 2789-8Google Scholar
- Calandra S, Oliva CP, Tarugi P, Bertolini S: APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency. Curr Opin Lipidol. 2006, 17 (2): 122-7.View ArticlePubMedGoogle Scholar
- Young SG, Davies BS, Fong LG, Gin P, Weinstein MM, Bensadoun A, Beigneux AP: GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons. Curr Opin Lipidol. 2007, 18 (4): 389-396.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang J, Hegele RA: Homozygous missense mutation (G56R) in glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPI-HBP1) in two siblings with fasting chylomicronemia (MIM 144650). Lipids Health Dis. 2007, 6: 23-View ArticlePubMedPubMed CentralGoogle Scholar
- Santamarina-Fojo S: The familial chylomicronemia syndrome. Endocrinol Metab Clin North Am. 1998, 27 (3): 551-67. viiiView ArticlePubMedGoogle Scholar
- Linares CL, Pelletier AL, Czernichow S, Vergnaud AC, Bonnefont-Rousselot D, Levy P, Ruszniewski P, Bruckert E: Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas. 2008, 37 (1): 13-12.View ArticleGoogle Scholar
- Palacios R, Santos J, Ruiz J, Marquez M: [Pancreatitis, triglycerides and highly-active antiretroviral therapy]. Med Clin. 2002, 118 (2): 77-78.View ArticleGoogle Scholar
- Hieronimus S, Benlian P, Bayer P, Bongain A, Fredenrich A: Combination of apolipoprotein E2 and lipoprotein lipase heterozygosity causes severe hypertriglyceridemia during pregnancy. Diabetes Metab. 2005, 31 (3): 295-7.View ArticlePubMedGoogle Scholar
- Sanduende Otero Y, Figueira Moure A, Rama-Maceiras P, Bautista Guillen A, Dieguez Fernandez M: [Hypertriglyceridemic pancreatitis and pregnancy]. Rev Esp Anestesiol Reanim. 2003, 50 (9): 477-480.PubMedGoogle Scholar
- Gursoy A, Kulaksizoglu M, Sahin M, Ertugrul DT, Ozer F, Tutuncu NB, Demirag NG: Severe hypertriglyceridemia-induced pancreatitis during pregnancy. J Natl Med Assoc. 2006, 98 (4): 655-657.PubMedPubMed CentralGoogle Scholar
- Hsuan-Hwai Lin, Chin-Hui Hsu, You-Chen Chao: Tamoxifen-Induced Severe Acute Pancreatitis: A Case Report. 2004, 49 (6): 997-999.Google Scholar
- Castro MR, Nguyen TT, O'Brien T: Clomiphene-induced severe hypertriglyceridemia and pancreatitis. Mayo Clin Proc. 1999, 74 (11): 1125-1128.View ArticlePubMedGoogle Scholar
- McCarter TL, Chen YK: Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy. Am J Gastroenterol. 1992, 87 (12): 1855-1858.PubMedGoogle Scholar
- Henneman P, Schaap FG, Rensen PCN, Dijk KWv, Smelt AHM: Estrogen induced hypertriglyceridemia in an apolipoprotein AV deficient patient. J Intern Med. 2008, 263 (1): 107-108.View ArticlePubMedGoogle Scholar
- Ross CJD, Twisk J, Meulenberg JM, Liu G, Oever Van Den K, Moraal E, Hermens WT, Rip J, Kastelein JJP, Kuivenhoven JA, Hayden MR: Long-Term Correction of Murine Lipoprotein Lipase Deficiency with AAV1-Mediated Gene Transfer of the Naturally Occurring LPLS447X Beneficial Mutation. Hum Gene Ther. 2004, 15 (9): 906-919.View ArticlePubMedGoogle Scholar
- Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, Maas MM, Zwinderman AH, Ross C, Aronica E, High KA, Levi MM, Hayden MR, Kastelein JJ, Kuivenhoven JA: Intramuscular Administration of AAV1-Lipoprotein LipaseS447X Lowers Triglycerides in Lipoprotein Lipase-Deficient Patients. Arterioscler Thromb Vasc Biol. 2008, 28 (12): 2303-2304.View ArticlePubMedGoogle Scholar
- Bachorik PS, Ross JW: National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary. The National Cholesterol Education Program Working Group on Lipoprotein Measurement. Clin Chem. 1995, 41 (10): 1414-20.PubMedGoogle Scholar
- Holm C, Olivecrona G, Ottosson M: Assays of lipolytic enzymes. Methods Mol Biol. 2001, 155: 97-119.PubMedGoogle Scholar
- Tornvall P, Olivecrona G, Karpe F, Hamsten A, Olivecrona T: Lipoprotein Lipase Mass and Activity in Plasma and Their Increase After Heparin Are Separate Parameters With Different Relations to Plasma Lipoproteins. Arterioscler Thromb Vasc Biol. 1995, 15 (8): 1086-1093.View ArticlePubMedGoogle Scholar
- Bengtsson-Olivecrona G, Olivecrona T: Phospholipase activity of milk lipoprotein lipase. Meth Enzymol. 1991, 197: 345-356.View ArticlePubMedGoogle Scholar
- Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990, 31 (3): 545-8.PubMedGoogle Scholar
- Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, Pennacchio LA, Humphries SE: Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet. 2002, 11 (24): 3039-3046.View ArticlePubMedGoogle Scholar
- Durrington P: Dyslipidaemia. The Lancet. 2003, 362 (9385): 717-731.View ArticleGoogle Scholar
- Brunzell JD, Bierman EL: Chylomicronemia syndrome. Interaction of genetic and acquired hypertriglyceridemia. Med Clin North Am. 1982, 66 (2): 455-68.View ArticlePubMedGoogle Scholar
- Chait A, Brunzell JD: Chylomicronemia syndrome. Adv Intern Med. 1992, 37: 249-273.PubMedGoogle Scholar
- Toskes PP: Hyperlipidemic pancreatitis. Gastroenterol Clin North Am. 1990, 19 (4): 783-791.PubMedGoogle Scholar
- Ghiselli G, Schaefer EJ, Zech LA, Gregg RE, Brewer HBJ: Increased prevalence of apolipoprotein E4 in type V hyperlipoproteinemia. J Clin Invest. 1982, 70 (2): 474-7.View ArticlePubMedPubMed CentralGoogle Scholar
- Cardona F, Morcillo S, Gonzalo-Marin M, Tinahones FJ: The Apolipoprotein E Genotype Predicts Postprandial Hypertriglyceridemia in Patients with the Metabolic Syndrome. J Clin Endocrinol Metab. 2005, 90 (5): 2972-2975.View ArticlePubMedGoogle Scholar
- Klos KLE, Hamon S, Clark AG, Boerwinkle E, Liu K, Sing CF: APOA5 polymorphisms influence plasma triglycerides in young, healthy African Americans and whites of the CARDIA Study. J Lipid Res. 2005, 46 (3): 564-571.View ArticlePubMedGoogle Scholar
- Pennacchio LA, Rubin EM: Apolipoprotein A5, a Newly Identified Gene That Affects Plasma Triglyceride Levels in Humans and Mice. Arterioscler Thromb Vasc Biol. 2003, 23 (4): 529-534.View ArticlePubMedGoogle Scholar
- Vrablik M, Horinek A, Ceska R, Adamkova V, Poledne R, Hubacek JA: Ser19->Trp polymorphism within the apolipoprotein AV gene in hypertriglyceridaemic people. J Med Genet. 2003, 40 (8): 105e-View ArticleGoogle Scholar
- Oliva CP, Pisciotta L, Volti GL, Sambataro MP, Cantafora A, Bellocchio A, Catapano A, Tarugi P, Bertolini S, Calandra S: Inherited Apolipoprotein A-V Deficiency in Severe Hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 2005, 25 (2): 411-417.View ArticleGoogle Scholar
- Marcais C, Verges B, Charriere S, Pruneta V, Merlin M, Billon S, Perrot L, Drai J, Sassolas A, Pennacchio LA, Fruchart-Najib J, Fruchart J, Durlach V, Moulin P: Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. J Clin Invest. 2005, 115 (10): 2862-2869.View ArticlePubMedPubMed CentralGoogle Scholar
- Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, Laatsch A, Heeren J: Apolipoprotein AV Accelerates Plasma Hydrolysis of Triglyceriderich Lipoproteins by Interaction with Proteoglycan-bound Lipoprotein Lipase. J Biol Chem. 2005, 280 (22): 21553-21560.View ArticlePubMedGoogle Scholar
- Henneman P, Schaap FG, Havekes LM, Rensen Patrick, Frants RR, Arie vT, Hattori H, August HM, Smelt Ko, Willems vD: Plasma apoAV levels are markedly elevated in severe hypertriglyceridemia and positively correlated with the APOA5 S19W polymorphism [abstract]. Atherosclerosis. 2007, 193: 129-134.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/9/46/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.